<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879122</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-9HX</org_study_id>
    <nct_id>NCT03879122</nct_id>
  </id_info>
  <brief_title>A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer</brief_title>
  <official_title>A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntax for Science, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic prostate cancer is an incurable disease that typically spreads beyond the&#xD;
      prostate. The standard of care is to systemically treat the disease with androgen deprivation&#xD;
      therapy (ADT). However, the disease progresses in virtually all patients to the state of&#xD;
      castration resistant prostate cancer (CRPC), with a median time to progression of 24 months.&#xD;
      Patients with high volume disease (with either visceral metastasis and/or bone metastasis)&#xD;
      exhibit a worse prognosis, with a median clinical progression of 14 months.&#xD;
&#xD;
      Recently, the CHAARTED and STAMPEDE studies demonstrated that the combination of Docetaxel&#xD;
      (chemotherapy) and ADT delayed the clinical progression and improved the survival a median of&#xD;
      14 months (17 for high volume patients). Nevertheless, the prognosis of patients with high&#xD;
      volume metastatic disease continues to be poor.&#xD;
&#xD;
      Meanwhile the immunotherapy, the use of antibodies that recognize tumoral cells and promote&#xD;
      the immune system activity against the cancer, has emerged as a very useful option in many&#xD;
      cancers. Among others, the antibodies Nivolumab and Ipilimumab have been approved for the&#xD;
      treatment of multiple types of cancer.&#xD;
&#xD;
      In this context, SOGUG (Spanish Oncology Genitourinary Group) has designed this new study&#xD;
      &quot;PROSTRATEGY&quot; with the objective of evaluating whether the addition of immunotherapy to&#xD;
      chemotherapy and ADT improves the prognosis and survival of patients with high volume&#xD;
      metastatic hormone-sensitive prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-arm multi-stage (MAMS), multi-centre randomised controlled trial with 3 arms (2 experimental arms and a control arm) and 4 stages (three intermediate and a final stage). In all 3 intermediate stages of the trial, each experimental arm is compared in a pairwise manner with the control arm using an &quot;intermediate&quot; outcome measure. Experimental arms that do not reach a predefined critical value are discontinued. In the final stage, the remaining(s) arm(s) will be compared with the control arm in terms of overall survival (definitive outcome). The 3 arms included in this trial are the Control arm (ARM 1): ADT plus 6 cycles of DOCETAXEL and 2 experimental arms: ADT plus DOCETAXEL plus NIVOLUMAB (ARM 2) and ADT plus IPILIMUMAB alternating with DOCETAXEL and with NIVOLUMAB (ARM 3). Other experimental arms could be included later.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA progression-free survival (PSA-PFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression-free survival (rPFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression-free survival (cPFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration resistant prostate cancer (TCRPC)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune radiological progression-free survival (irPFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune clinical progression-free survival (icPFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to immune castration resistant prostate cancer (TiCRPC)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic skeletal-related event free survival (SSREFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of each of the treatment arms by assessing Adverse Events</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>EQ-5D Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>FACT-P Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>BPI Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Metastatic Hormone-sensitive Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ADT + Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + Docetaxel + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + Ipilimumab / Docetaxel + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab 5 MG/ML</intervention_name>
    <description>Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)</description>
    <arm_group_label>ADT + Ipilimumab / Docetaxel + Nivolumab</arm_group_label>
    <other_name>YERVOY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 10 MG/ML</intervention_name>
    <description>Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered</description>
    <arm_group_label>ADT + Docetaxel + Nivolumab</arm_group_label>
    <arm_group_label>ADT + Ipilimumab / Docetaxel + Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.&#xD;
In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.</description>
    <arm_group_label>ADT + Docetaxel</arm_group_label>
    <arm_group_label>ADT + Docetaxel + Nivolumab</arm_group_label>
    <arm_group_label>ADT + Ipilimumab / Docetaxel + Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT (androgen deprivation therapy)</intervention_name>
    <description>Androgen deprivation therapy per the standard of care</description>
    <arm_group_label>ADT + Docetaxel</arm_group_label>
    <arm_group_label>ADT + Docetaxel + Nivolumab</arm_group_label>
    <arm_group_label>ADT + Ipilimumab / Docetaxel + Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be at least 18 years of age&#xD;
&#xD;
          2. Signed and dated written informed consent, obtained before the performance of any&#xD;
             protocol-related procedure.&#xD;
&#xD;
          3. Histological or cytological diagnosis of prostate cancer with an elevated PSA level&#xD;
             and radiologic evidence of metastatic disease.&#xD;
&#xD;
          4. ECOG performance-status score of 0, 1, or 2. Patients with a score of 2 are eligible&#xD;
             if the decrement in functioning was due to prostate cancer.&#xD;
&#xD;
          5. Metastatic disease that has spread beyond the prostate or relapsed after local&#xD;
             therapy, documented by body CT scan and/or bone scan, according to PCWG 3 criteria,&#xD;
             with high volume according to criteria used in the CHAARTED study.&#xD;
&#xD;
          6. Radiological and scintigraphic studies to identify initial evaluable disease should be&#xD;
             done as follows:&#xD;
&#xD;
               -  If ADT has not been initiated, CT scans and bone scan must be obtained within 6&#xD;
                  weeks prior to the start of ADT.&#xD;
&#xD;
               -  If all required imaging had not been completed prior to starting ADT, any&#xD;
                  additional scan must be obtained after starting androgen deprivation but prior to&#xD;
                  randomization and the initiation of docetaxel (It is assumed that the scans of&#xD;
                  patients with high volume disease would not normalize in less than 120 days to&#xD;
                  the point that a patient would go from &quot;high volume&quot; to &quot;low volume&quot;).&#xD;
&#xD;
          7. Measurable or evaluable disease according to the PWGC 3.&#xD;
&#xD;
          8. Patients who started ADT for metastatic disease are eligible if ADT commenced within&#xD;
             120 days before randomization, they have not started docetaxel chemotherapy yet, and&#xD;
             there was no evidence of clinical, radiological or biochemical progression after ADT.&#xD;
&#xD;
          9. Patients receiving ADT in the adjuvant and/or neoadjuvant setting for less than 30&#xD;
             months of therapy, AND the effect of the last depot injection had expired at least 12&#xD;
             months prior to documentation of metastatic disease, AND&#xD;
&#xD;
               -  They had no evidence of disease (PSA &lt; 0.2 ng/dL) after prostatectomy plus&#xD;
                  hormonal therapy, or&#xD;
&#xD;
               -  PSA was &lt; 0.5 ng/dL after completing radiation therapy plus adjuvant or&#xD;
                  neoadjuvant hormonal therapy, and had not doubled above nadir in at least 12&#xD;
                  months.&#xD;
&#xD;
         10. Patients must have adequate organ function within 4 weeks prior to randomization and&#xD;
             evidenced by:&#xD;
&#xD;
               -  Absolute Neutrophil Count &gt; 1500/mm 3&#xD;
&#xD;
               -  Platelet count &gt; 100,000/mm 3&#xD;
&#xD;
               -  Creatinine clearance (CrCl)&gt; 30 mL/min calculated at screening using the&#xD;
                  Cockcroft- Gault formula: Creatinine clearance for mule (mL/min) = (140- age in&#xD;
                  years)(body weight in kg)/[72x(serum creatinine in mg/dl).&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 ULN (&lt; 3.0 mg/dl in patients with Gilbert´s Syndrome).&#xD;
&#xD;
               -  Prothrombin time or INR and PTT &lt; 1.5 x ULN, except if on therapeutic anti-&#xD;
                  coagulation in which case the patient can be enrolled if stable and&#xD;
                  anti-coagulation levels are appropriate for their condition per good clinical&#xD;
                  practice.&#xD;
&#xD;
               -  ALT and AST &lt; or = 3 x ULN (or &lt; or = 5 if liver metastases)&#xD;
&#xD;
         11. At least 4 weeks should have passed after major surgery prior to randomization, and&#xD;
             the patient should be recovered from all side effects and complications.&#xD;
&#xD;
         12. Men who are sexually active with WOCBP must agree to follow instructions for methods&#xD;
             of contraception for the duration of treatment with study drug plus 5 half-lives of&#xD;
             study drug plus 90 days (duration of sperm turnover) for a total of 31 weeks&#xD;
             post-treatment completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are not eligible if the PSA has risen from its lowest point, between the&#xD;
             beginning of androgen deprivation therapy and the date of randomization, and met&#xD;
             criteria for progression as defined in the protocol.&#xD;
&#xD;
          2. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody,&#xD;
             PROSTVAC, Sipuleucel-T or any previous immunotherapy or vaccines for cancer.&#xD;
&#xD;
          3. Prior chemotherapy in the adjuvant or neoadjuvant setting.&#xD;
&#xD;
          4. Unable to receive docetaxel at full doses at investigator criteria.&#xD;
&#xD;
          5. Peripheral neuropathy grade &gt; 1.&#xD;
&#xD;
          6. All toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia&#xD;
             or fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before&#xD;
             administration of study drug. Subjects with toxicities attributed to prior surgery or&#xD;
             radiotherapy, which are not expected to resolve and result in long-term lasting&#xD;
             sequelae, are permitted to enrol.&#xD;
&#xD;
          7. History of hypersensitivity reaction to Docetaxel®, other drugs formulated with&#xD;
             polysorbate 80, or monoclonal antibodies.&#xD;
&#xD;
          8. Prior hormone therapy or immunotherapy in the metastatic setting.&#xD;
&#xD;
          9. Prior palliative radiation therapy within 30 days of starting docetaxel.&#xD;
&#xD;
         10. Known acute or chronic HIV, Hepatitis B, or Hepatitis C. Past Hepatitis B infection&#xD;
             with no signs of activity later, are allowed&#xD;
&#xD;
         11. Active brain metastases or leptomeningeal metastases, except if they have been treated&#xD;
             and there is a magnetic resonance imaging (or CT scan if MRI were contraindicated)&#xD;
             showing no evidence of progression for at least 4 weeks after the treatment&#xD;
&#xD;
         12. Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days previous to randomization. Inhaled or topical steroids and adrenal replacement&#xD;
             doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             autoimmune disease.&#xD;
&#xD;
         13. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are allowed.&#xD;
&#xD;
         14. Active cardiac disease defined as active angina, symptomatic congestive heart failure,&#xD;
             or myocardial infarction within the previous six months&#xD;
&#xD;
         15. History of malignancy in the past 5 years except for basal cell and squamous cell&#xD;
             carcinoma of the skin and non-muscle-invasive bladder cancer. Other more malignancies&#xD;
             considered to have a low potential to progress may be enrolled if approved by study&#xD;
             chair.&#xD;
&#xD;
         16. Any serious or uncontrolled medical disorder that, in the opinion of the investigator,&#xD;
             may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the subject to receive protocol therapy, or&#xD;
             interfere with the interpretation of study results.&#xD;
&#xD;
         17. Participation in another clinical trial within 30 days prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Condition is exclusive of males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Ángel Arranz Arija, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician - Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hestia Duran I Reynals</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu (Althaia Manresa)</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08242</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General, Materno E Infantil Reina</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>San Sebastián De Los Reyes</city>
        <state>Madrid</state>
        <zip>28072</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <state>Valenci</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

